![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZCCHC3 |
Gene summary for ZCCHC3 |
![]() |
Gene information | Species | Human | Gene symbol | ZCCHC3 | Gene ID | 85364 |
Gene name | zinc finger CCHC-type containing 3 | |
Gene Alias | C20orf99 | |
Cytomap | 20p13 | |
Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | Q9NUD5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
85364 | ZCCHC3 | HCC1_Meng | Human | Liver | HCC | 1.95e-39 | 4.77e-02 | 0.0246 |
85364 | ZCCHC3 | HCC2_Meng | Human | Liver | HCC | 3.80e-09 | 5.00e-02 | 0.0107 |
85364 | ZCCHC3 | HCC2 | Human | Liver | HCC | 2.63e-04 | 1.84e+00 | 0.5341 |
85364 | ZCCHC3 | S014 | Human | Liver | HCC | 1.79e-09 | 4.00e-01 | 0.2254 |
85364 | ZCCHC3 | S015 | Human | Liver | HCC | 2.57e-10 | 5.53e-01 | 0.2375 |
85364 | ZCCHC3 | S016 | Human | Liver | HCC | 2.02e-10 | 4.47e-01 | 0.2243 |
85364 | ZCCHC3 | S028 | Human | Liver | HCC | 7.74e-07 | 3.19e-01 | 0.2503 |
85364 | ZCCHC3 | S029 | Human | Liver | HCC | 2.17e-03 | 2.76e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003052222 | Liver | HCC | intracellular receptor signaling pathway | 171/7958 | 265/18723 | 3.00e-13 | 1.61e-11 | 171 |
GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
GO:0039528 | Liver | HCC | cytoplasmic pattern recognition receptor signaling pathway in response to virus | 30/7958 | 34/18723 | 3.88e-08 | 8.39e-07 | 30 |
GO:00027533 | Liver | HCC | cytoplasmic pattern recognition receptor signaling pathway | 46/7958 | 60/18723 | 7.37e-08 | 1.49e-06 | 46 |
GO:00022211 | Liver | HCC | pattern recognition receptor signaling pathway | 107/7958 | 172/18723 | 1.37e-07 | 2.58e-06 | 107 |
GO:00395291 | Liver | HCC | RIG-I signaling pathway | 24/7958 | 27/18723 | 7.23e-07 | 1.12e-05 | 24 |
GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
GO:00985861 | Liver | HCC | cellular response to virus | 57/7958 | 84/18723 | 2.30e-06 | 3.11e-05 | 57 |
GO:00324814 | Liver | HCC | positive regulation of type I interferon production | 41/7958 | 58/18723 | 1.29e-05 | 1.44e-04 | 41 |
GO:0032479 | Liver | HCC | regulation of type I interferon production | 60/7958 | 95/18723 | 3.84e-05 | 3.80e-04 | 60 |
GO:0032606 | Liver | HCC | type I interferon production | 60/7958 | 95/18723 | 3.84e-05 | 3.80e-04 | 60 |
GO:0039531 | Liver | HCC | regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 20/7958 | 24/18723 | 4.92e-05 | 4.70e-04 | 20 |
GO:00028312 | Liver | HCC | regulation of response to biotic stimulus | 173/7958 | 327/18723 | 8.55e-05 | 7.48e-04 | 173 |
GO:00395351 | Liver | HCC | regulation of RIG-I signaling pathway | 17/7958 | 20/18723 | 1.18e-04 | 9.87e-04 | 17 |
GO:00622072 | Liver | HCC | regulation of pattern recognition receptor signaling pathway | 59/7958 | 105/18723 | 3.18e-03 | 1.47e-02 | 59 |
GO:00450881 | Liver | HCC | regulation of innate immune response | 113/7958 | 218/18723 | 3.27e-03 | 1.50e-02 | 113 |
GO:0071359 | Liver | HCC | cellular response to dsRNA | 16/7958 | 22/18723 | 4.03e-03 | 1.76e-02 | 16 |
GO:0002218 | Liver | HCC | activation of innate immune response | 32/7958 | 52/18723 | 4.35e-03 | 1.89e-02 | 32 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZCCHC3 | SNV | Missense_Mutation | novel | c.1034G>C | p.Ser345Thr | p.S345T | Q9NUD5 | protein_coding | tolerated(0.05) | benign(0.054) | TCGA-37-A5EL-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | temodal | PD |
ZCCHC3 | SNV | Missense_Mutation | novel | c.966N>C | p.Glu322Asp | p.E322D | Q9NUD5 | protein_coding | tolerated(0.82) | benign(0.06) | TCGA-56-7579-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | PD |
ZCCHC3 | SNV | Missense_Mutation | novel | c.526N>C | p.Gly176Arg | p.G176R | Q9NUD5 | protein_coding | deleterious(0.03) | benign(0.202) | TCGA-66-2783-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | CR |
ZCCHC3 | SNV | Missense_Mutation | novel | c.854N>G | p.Lys285Arg | p.K285R | Q9NUD5 | protein_coding | tolerated(0.3) | benign(0.19) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZCCHC3 | SNV | Missense_Mutation | novel | c.1064N>A | p.Arg355Lys | p.R355K | Q9NUD5 | protein_coding | tolerated(0.47) | benign(0.025) | TCGA-HU-A4GC-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
ZCCHC3 | SNV | Missense_Mutation | novel | c.1192N>G | p.Thr398Ala | p.T398A | Q9NUD5 | protein_coding | tolerated_low_confidence(0.09) | benign(0.037) | TCGA-VQ-A8PX-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |